Phase 2/3 Study of IGSC, 20% in PIDD

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

January 28, 2013

Primary Completion Date

March 13, 2015

Study Completion Date

March 13, 2015

Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
BIOLOGICAL

Immune Globulin Intravenous (Human), 10% Solution

Intravenous infusion with IGIV, 10%

DRUG

Immune Globulin Subcutaneous (Human), 20% Solution

Subcutaneous infusion with IGSC, 20%

Trial Locations (18)

10461

Montefiore Medical Center Division of Allergy/Immunology, The Bronx

30322

Emory University, Atlanta

33408

Allergy Associates of the Palm Beaches, North Palm Beach

40215

Family Allergy and Asthma Research Institute, Louisville

53226

Medical College of Wisconsin, Milwaukee

55446

Midwest Immunology Clinical and Infusion Center, Plymouth

60612

Rush University Medical Center, Chicago

63104

SSM Cardinal Glennon Children's Medical Center, St Louis

70118

Children's Hospital New Orleans- LSUHSC School of Medicine, New Orleans

73131

Oklahoma Institute of Allergy and Asthma Clinical Research, Oklahoma City

74136

Vital Prospects Clinical Research Institute, PC, Tulsa

75063

Allergy Asthma and Immunology Clinic PA, Irving

75230

Dallas Allergy Immunology Research, Dallas

80112

IMMUNOe International Research Centers, Centennial

84041

Rocky Mountain Asthma/Allergy/Immunology, Layton

92697

University of California, Irvine, Irvine

H3H 1C5

Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montreal

HEH 1P3

Montreal Children's Hospital- McGill University health Center, Montreal

All Listed Sponsors
lead

Baxalta now part of Shire

INDUSTRY

NCT01218438 - Phase 2/3 Study of IGSC, 20% in PIDD | Biotech Hunter | Biotech Hunter